NeurologyLive® Friday 5 — November 7, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C

The chief medical officer at Mandos Health discussed new CNS 2025 data on adrabetadex in infantile-onset Niemann-Pick type C and the growing evidence of its potential disease-modifying impact.

2: Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS

The associate professor of neurology at Yale School of Medicine discussed 52-week data from the phase 3 MINT trial of inebilizumab in patients with generalized myasthenia gravis. [WATCH TIME: 5 minutes]

3: New Guidelines Aim to Redefine Penetrating Brain Injury Care

Gregory Hawryluk, MD, PhD, a neurosurgeon at Cleveland Clinic, spoke on the development and clinical impact of new global guidelines for penetrating traumatic brain injury.

4: NeuroVoices: John Norbury, MD, on Training the Next Generation of Neuromuscular Specialists

The associate professor of physical medicine and rehabilitation at Virginia Commonwealth University discussed his passion for educating others about electrodiagnosis and ultrasound in neuromuscular disorders.

5: Understanding the Global Impact of the Honolulu Asian Aging Study: George W. Ross, MD

An investigator at Kuakini Health Systems spoke about the global importance of the Honolulu-Asia Aging Study, highlighting its history and findings, including data surrounding the diagnosis of neurodegenerative diseases. [WATCH TIME: 11 minutes]